Chinese Approach on Medical Treatment against COVID-19

2020-04-16 21:04:35 来源: International Union for Science and Technology Communication 作者: Cao Xiuying Liu Yin & Long Yun

Is there any specific drug to fight against COVID-19? When can we get access to the specific drug? These two questions are hard to answer for now. Developing the specific drug is quite tough. It is  not practical when R&D works of new drugs usually takes too long and costs too much.

Chinese scientists realized screening existing drugs for new uses is a faster approach to combat COVID-19.

The researchers quickly selected 5,000 potentially effective drugs from more than 70,000 drugs or compounds, and then screened 100 drugs to carry out in vivo experiments of novel coronavirus activity. Every essential step of clinical trials and safety evaluation for drug development should be ensured in the process of new uses for existing drugs. All related R&D activities adhere to the principles of safety, efficacy and accessibility.

"All the current drugs used in clinical application have undergone rigorous safety research and evaluation. The indications, contraindications and adverse reactions are specified in the drug instructions. Users' safety can be guaranteed if they strictly follow treatment methods listed in the instructions and the diagnosis and treatment plan," Zhang Xinmin, Director of the Biology Center of the Ministry of Science and Technology (MOST), told Science and Technology Daily.

"To prevent mild and ordinary cases turning into severe cases, we focused on promoting Chloroquine Phosphate, Familavir and traditional Chinese medicine (TCM). The clinical application of convalescent plasma therapy, Tocilizumab, stem cells therapy and artificial liver therapy are promoted to treat patients in severe and critical condition. So far, we have achieved progress in both situations," Zhang Xinmin said.

The antimalarial drug Chloroquine Phosphate and the anti-influenza drug Arbidol have been included in the sixth version of the COVID-19 diagnosis and treatment guidelines. Tocilizumab, which was originally used to treat moderate to severe rheumatoid arthritis, has been included in the seventh version of the guidelines. Currently, it is used to treat severe patients. Fapiravir has completed clinical research and shown good efficacy. After being fully demonstrated, it has been officially recommended to be included in the COVID-19 diagnosis and treatment guidelines as soon as possible.

Zhang said that the application of the research achievements and China's medical treatment plan will be promoted in response to the current pandemic.

It is worth mentioning that traditional Chinese medicine (TCM) plays an important role in Chinese approach to fight against COVID-19.

"Xuanfeibaidu Granule is a prescription based on a combination of medical literature, clinical experience, and drug screening. We initiated a program of developing new granular drugs based on the formula of Xuanfeibaidu which has good clinical efficacy," Said Zhang Boli, member of the Central Guidance Team, academician of the Chinese Academy of Engineering (CAE) and president of Tianjin University of TCM. He and Liu Qingquan, who is also a member of Central Guidance Team and president of the Beijing Hospital of TCM, swiftly conducted syndrome research, and on this basis carried out evaluation research on the clinical efficacy of traditional Chinese medicine (TCM), as well as drug screening and new drug development.

At present, Zhang Boli's team has collected 65 kinds of marketed Chinese patent medicines for anti-influenza and anti-pneumonia, and completed the preparation of Chinese patent medicine components, virtual screening combined with in vitro evaluation, cytokine storm cell model and anti-pulmonary fibrosis cell model establishment.

加载更多>>
责任编辑: 房琳琳
科技专题 更多>>
国内 更多>>

引入“互联网+”的理念&...

为丰富老年学员的文娱生活,搭建老年学员展示平台,宣传老年大学办学成果,山东省老年大学协会举办了“摩罗...

让课外书点燃乡村小学孩...

微信支付用户可进入“知识星光”小程序收集星光,集满99颗星光就能为乡村小学的孩子捐赠一本课外书,还可以...

聚焦三大社会问题,用AI...

《2019年全国未成年人互联网使用情况研究报告》显示,目前46%的未成年人表示曾遭遇不良网络信息,他们受到网...

打造中国生物医药产业的...

近年来,随着智能科技的迅猛发展,越来越多的科技型企业开始涉足生物医药领域。12月26日,中国工程院院士、...

数字时代,让我们与网络...

据《中国未成年人互联网运用报告(2020)》显示,未成年人的互联网普及率已达99.2%。未成年人首次触网年龄不...

科报集萃 更多>>

格力“再掀11.11”:给更...

11月26日晚,格力电器发布《“再掀11.11 百亿大让利”公告》,宣布从11月27日开始,按照与“11.11”当天同类...

GES大会“新好论道”,共...

11月25日,由中国发展研究基金会、北京师范大学、腾讯、GSV(全球硅谷投资公司)、新东方、好未来联合主办的...

喜获青少年足球产业推力...

11月16日,2019CIYF国际青少年足球嘉年华暨第二届青少年足球运动奖颁奖典礼在厦门举行。格力电器凭借在少年...

首届中国数据安全和治理...

近日,中国信息协会信息安全专业委员会2019年年会暨首届中国数据安全和治理高峰论坛在北京召开。本届峰会以...